Recently, immune-oncologic therapy advanced rapidly and has been defined as another option, following surgery, radiotherapy, chemotherapy and molecular targeted therapy, for treatment of malignant diseases. To date, several immune checkpoint inhibitors and compounds have been approved to treat various of malignant diseases with efficiency. Meanwhile, more and more potential therapeutic targets in processes of the cancer immunity have been noticed. We aimed to summarize the research status and clinical prospects of novel immune-oncologic treatment agencies targeted to different steps of the cancer-immunity cycle.
|Original language||English (US)|
|Number of pages||7|
|Journal||Chinese Journal of Lung Cancer|
|State||Published - Jan 1 2017|
- Immune checkpoint inhibitor
- Immuno-oncology therapy